Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (Zhongshan Hospital, Fudan University)
- Development stage
- Unknown
- Lead developer
- Zhongshan Hospital, Fudan University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Fecal microbiota transplant (FMT) is a microbial therapy being evaluated by Shanghai Zhongshan Hospital for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). The intervention utilizes a capsulized formulation of washed fecal microbiota to reconstruct the patient's gut microbiome. This strategy is intended to enhance the therapeutic efficacy and safety of immune checkpoint inhibitors, specifically anti-PD-1 and anti-PD-L1 monoclonal antibodies, by modulating the host's immune environment. In clinical trials, this FMT product is administered orally in combination with standard-of-care immunotherapy (anti-PD-1 or anti-PD-L1 antibodies) and platinum-based chemotherapy to patients who have achieved stable disease after first-line treatment.
- Other names
- FMTGut Microbiota reconstructionCapsulized Fecal Microbiota Transplant
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on fecal microbiota transplant (Zhongshan Hospital, Fudan University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (Zhongshan Hospital, Fudan University).